Lunai Bioworks Reports 35% Improvement In Alzheimer's Diagnostic Accuracy Via Augusta AI; Launches Preclinical Program For Early Intervention

Lunai Bioworks (NASDAQ:LNAI) today announced a major advance in Alzheimer's research: its AI platform, Augusta™, achieved up to a 35% improvement in diagnostic accuracy by combining MRI scans with genetic and metabolic data. The company is launching a preclinical Alzheimer's program to bring this technology closer to clinical use, a move that could enable earlier intervention for millions worldwide.

The new program builds on Lunai's recent announcement regarding their findings for Parkinson's Disease, and fulfills their broader vision of applying advanced, multi-modal ML to improve diagnostics in complex disease areas. BioSymetrics, a wholly-owned subsidiary of Lunai and creators of the Augusta platform, is currently engaged in ongoing collaborations with research institutions and pharmaceutical companies to translate these findings into actionable biomarkers and clinical tools, including its first commercial contract to identify early markers of Alzheimer's disease signed last week.

By combining genetic, metabolic, and imaging data using distributed ML pipelines, BioSymetrics has shown that models built on integrated datasets significantly outperform those built on any single modality. This work, benchmarked using the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset, confirms the value of Augusta's proprietary approach to heterogeneous data integration in neurodegenerative disease research.